Richard W. Paul & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Richard W. Paul & Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01K	Hold	19	–	–	﹤0.01%	274
2026 Q1	$2.43K	Hold	19	–	–	﹤0.01%	265
2025 Q4	$2.32K	Sell	19 -25	-57%	-$2.87K	﹤0.01%	257
2025 Q3	$4.41K	Sell	44 -295	-87%	-$26.6K	﹤0.01%	251
2025 Q2	$28.1K	Buy	339 +89	+36%	+$7.1K	0.01%	205
2025 Q1	$20.3K	Hold	250	–	–	0.01%	214
2024 Q4	$22.5K	Hold	250	–	–	0.01%	249
2024 Q3	$24.7K	Hold	250	–	–	0.01%	240
2024 Q2	$23.2K	Hold	250	–	–	0.01%	240
2024 Q1	$23.7K	Buy	250 +135	+117%	+$12.5K	0.01%	249
2023 Q4	$10.3K	Hold	115	–	–	﹤0.01%	302
2023 Q3	$8.4K	Buy	115 +55	+92%	+$4.39K	﹤0.01%	302
2023 Q2	$4.99K	Hold	60	–	–	﹤0.01%	364
2023 Q1	$4.57K	Buy	+60	New	+$4.98K	﹤0.01%	380

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Richard W. Paul & Associates's XBI Position: Q2 2026 in Review

Richard W. Paul & Associates held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 19 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

Richard W. Paul & Associates first reported a position in XBI in Q1 2023 and has held it in 14 quarters since. The position peaked at $28.1K in Q2 2025. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Richard W. Paul & Associates held 19 shares of State Street SPDR S&P Biotech ETF worth $3.01K as of Q2 2026.
Richard W. Paul & Associates left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Richard W. Paul & Associates's portfolio in Q2 2026, its #274 holding.
Richard W. Paul & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 14 quarters since.
Richard W. Paul & Associates's State Street SPDR S&P Biotech ETF position peaked at $28.1K in Q2 2025.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Richard W. Paul & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.